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Abstract
Exposure to arsenic affects large human populations worldwide, and has been associated with a
long list of human diseases, including skin, bladder, lung, and liver cancers, diabetes, and
cardiovascular disorders. In addition, there are large individual differences in susceptibility to
arsenic-induced diseases, which are frequently associated with different patterns of arsenic
metabolism. Several underlying mechanisms, such as genetic polymorphisms and epigenetics,
have been proposed, as these factors closely impact the individuals' capacity to metabolize arsenic.
In this context, the role of the gut microbiome in directly metabolizing arsenic and triggering
systemic responses in diverse organs raises the possibility that perturbations of the gut microbial
communities affect the spectrum of metabolized arsenic species and subsequent toxicological
effects. In this study, we used an animal model with altered gut microbiome induced by bacterial
infection, 16S rRNA gene sequencing and inductively coupled plasma mass spectrometry (ICP-
MS)-based arsenic speciation to examine the effect of gut microbiome perturbations on the
biotransformation of arsenic. Metagenomics sequencing revealed that bacterial infection
significantly perturbed the gut microbiome composition in C57BL/6 mice, which in turn resulted
in altered spectra of arsenic metabolites in urine, with inorganic arsenic species, methylated and
thiolated arsenic being perturbed. These data clearly illustrated that gut microbiome phenotypes
significantly affected arsenic metabolic reactions, including reduction, methylation and thiolation.
These findings improve our understanding of how infectious diseases and environmental exposure
interact, and may also provide novel insight regarding the gut microbiome composition as a new
risk factor of individual susceptibility to environmental chemicals.
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1. Introduction
Exposure to arsenic affects large human populations worldwide through the contamination
of drinking water by geological sources of inorganic arsenic. Hundreds of millions of people
around the world, especially in South and East Asia, drink water with inorganic arsenic
levels that far exceed the 10 μg/L guideline, established or accepted by WHO and US EPA.1
In the United States, as many as 25 million people are estimated to drink water with an
arsenic level above 10 μg/L, as private wells are not regulated by EPA and other agencies.2
Arsenic exposure has been associated with a number of diseases, such as skin, bladder, lung,
and liver cancers, diabetes, as well as cardiovascular disorders and reproductive defects.1,3-5
More recently, arsenic exposure has been linked to an increased incidence of diabetes in
animal models and human population studies.6,7 Numerous mechanisms, including the
interaction with sulfur, oxidative stress, genotoxicity, altered DNA repair and signal
transduction, cell proliferation and epigenetics, have been proposed for arsenic-induced
diseases.1,3,8-10 In addition, there are large differences in susceptibility to arsenic-induced
diseases among individuals,11,12 with several underlying mechanisms, such as genetic
polymorphisms, epigenetics and nutrition homeostasis, being proposed. Individual
susceptibility is frequently associated with different spectra of arsenic metabolism.
Accumulating evidence indicates that perturbations of the gut microbiome and functions
may play an important role in the development of human diseases. The essential role of the
gut microbiome in a variety of aspects of human health and metabolic processing of
xenobiotics raise the possibility that gut microbiome phenotypes affect the
biotransformation of arsenic. This hypothesis is supported by several previous studies that
have clearly demonstrated the involvement of the gut microbiome in reduction, methylation
and thiolation of arsenic species.13,14
The human body harbors 100 trillion gut microbes, ∼10-times more than all human cells.15
It is estimated that the ∼500-1000 species residing in the human gut encode 100-fold more
unique genes than our human genome. The gut microbiota has important functions in
metabolic processing, energy production, immune cell development, food digestion,
epithelial homeostasis, and so forth.16,17 Mounting evidence indicates that dysregulated gut
microflora contributes to a variety of diseases, including diabetes, obesity, cardiovascular
diseases, allergies, inflammatory bowel disease and others.18-21 The composition of the gut
microbiome is highly diverse, and this diversity can be readily affected by external factors,
such as environment, diet, bacterial/viral infection and antibiotics. Furthermore, previous
studies have shown that altered gut microflora dramatically changed activities of diverse
enzymes in the liver, including P450s and phase II enzymes responsible for the metabolic
activation of xenobiotics.22 This raises the possibility that gut microbiome phenotypes play
a role in defining individual response via altering metabolic capacity in the host when
exposed to environmental chemicals.
In particular, inorganic arsenic is metabolized via a series of methylation and reduction
reactions, with S-adenosylmethionine (SAM) as the main methyl donor.23,24 The widely-
accepted metabolic pathway of inorganic arsenic consists of alternating reduction from
pentavalent arsenic to trivalent and oxidative methylation of the trivalent arsenic
metabolites. The six arsenic species involved in this pathway in humans are inorganic
arsenic (iAsV and iAsIII), monomethylarsonic acid (MMAsV), monomethylarsonous acid
(MMAsIII), dimethylarsinic acid (DMAsV) and dimethylarsinous acid (DMAsIII). In
addition to arsenic metabolism catalyzed by specific enzymes, such as arsenic (+3 oxidation
state) methyltransferase (As3mt), in diverse tissues,25 a few experiments have demonstrated
that the gut microbiome participates in the metabolism of arsenic species.13,14,26,27 For
example, Rowland and Davies reported the reduction of iAsV to iAsIII, as well as the
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formation of MMAs and DMAs, by rat cecal bacteria.28 Likewise, the thiolation of
methylated As oxides in the cecal contents of a mouse 13 and the in vivo thiolation of
arsenic have been reported.29-31 More recently, Van de Wiele, et al., found a high degree of
methylation of iAs and As-contaminated soils by human gut microbiota.14 Besides the
formation of MMAsV, they also detected the formation of highly toxic MMAsIII, and
microbial thiolated monomethylmonothioarsonic acid (MMMTAsV).14
Given the role of the gut microbiome in direct metabolic reactions of arsenic and triggered
systemic responses in other organs, we thus hypothesize that perturbations of the gut
microbial community affect the spectrum of metabolized arsenic species and subsequent
toxicological responses. In the present study, we used an animal model with altered gut
microbiome, 16S rRNA gene sequencing and ICP-MS-based arsenic speciation to examine
the effect of gut microbiome perturbations on the biotransformation of arsenic.
Metagenomics sequencing revealed that bacterial infection significantly perturbed the gut
microbiome composition in C57BL/6 mice, which in turn resulted in altered spectra of
arsenic metabolites, with inorganic arsenic species and methylated arsenic being up-
regulated and down-regulated, respectively. These data clearly illustrated that gut
microbiome perturbations arising from bacterial infection significantly affect the metabolism
of arsenic. These findings may provide novel insight regarding the gut microbiome
composition as a new risk factor of individual susceptibility to environmental chemicals.
2. Materials and Methods
Chemicals
Sodium arsenite and arsenobetaine (AsB) were obtained from Fisher Scientific (Pittsburgh,
PA) and Sigma-Aldrich (Milwaukee, WI), respectively. Dimethylarsinic acid (DMAsV) and
disodium monomethylarsonate (MMAsV) were obtained from Chem Service (West Chester,
PA). MMAsIII (oxomethylarsine), DMAsIII (iododimethylarsine), dimethylmonothioarsinic
acid (DMTAs) and trimethyl arsine oxide (TMAsO) were provided by Professor William
Cullen, University of British Columbia (Canada). Other reagents used for the HPLC mobile
phase and diluent were Puratonic® 99.999% purity grade ammonium carbonate (Alfa Aesar,
Ward Hill, MA), ammonium sulfate (Mallinckrodt, Hazelwood, MO), and ammonium
acetate (ICN Biochemicals, Aurora, OH).
Animal infection and exposure
Helicobacter-free C57BL/6 (∼8 weeks old) mice were purchased from Jackson Laboratories
(Bar Harbor, ME). Mice were provided pelleted rodent diet (ProLab 3000; Purina Mills, St.
Louis, MO) and filtered water ad libitum and were maintained in AAALAC accredited
facilities in microisolator caging under standard environmental conditions. All experiments
were approved by the MIT Committee on Animal Care. Each grouping comprised 10 mice
unless otherwise stated. Mice (Groups B and C only, Figure 1) were dosed at 9 to 10 weeks
of age with 2 × 107 H. trogontum three times on alternate days by oral gavage. Inorganic
arsenic (10 ppm) was then administered to mice (Groups B and D only, Figure 1) through
drinking water for 4 weeks. The helicobacter infection status of these separately housed
colonies was confirmed by fecal PCR at the end of the study. Urine samples were collected
using a metabolic cage with dry ice placed around the urine collection vessel to prevent
oxidation or degradation of metabolites during the collection period (∼16 h). Fecal pellets
were also collected from individual animals. Plasma samples and tissues were collected
during necropsy at the end of the study.
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Animal monitoring and histological analysis
Throughout the experiments, mice were assessed for evidence of diarrhea, dehydration, and
deteriorating body condition. Mice were euthanized with CO2 and necropsied after 4 weeks
of arsenic consumption. Formalin-fixed tissues were routinely processed, embedded in
paraffin, sectioned at 4 μm, stained with hematoxylin and eosin, and evaluated by a board-
certified veterinary pathologist blinded to the sample identity. Inflammation, edema,
epithelial defects, hyperplasia, and dysplasia of multiple regions of liver and colon were
scored on an ascending scale (0 to 4, with 0 being normal) of severity and invasiveness of
the lesion if any.
16S rRNA metagenomics sequencing
DNA was isolated from fecal pellets using a PowerSoil® DNA Isolation Kit as instructed by
the manufacturer (MO BIO Laboratories, CA). The resultant DNA was quantified by a UV
spectroscopy and stored at -80°C for further analysis. DNA was amplified using universal
primers of U515 (GTGCCAGCMGCCGCGGTAA) and E786
(GGACTACHVGGGTWTCTAAT) to target the V4 regions of 16S rRNA of bacteria.
Individual samples were barcoded, pooled to construct the sequencing library, followed by
sequencing with an Illumina Miseq to generate pair-ended 150 × 150 reads.
Data analysis of 16s rRNA sequencing data
The raw mate-paired fastq files were quality-filtered, demultiplexed and analyzed using
Quantitative Insights into Microbial Ecology (QIIME).32 For quality filtering, the default
parameters of QIIME were maintained in which reads with a minimum Phred quality score
less than 20, containing ambiguous base calls and containing fewer than 113bp of
consecutive high quality base calls, were discarded.
Additionally, reads with three consecutive low quality bases were truncated. The samples
sequenced were demultiplexed using 8bp barcodes, allowing 1.5 errors in the barcode.
UCLUST was used to choose the Operational Taxonomic Units (OTUs) with a threshold of
97% sequence similarity.33 A representative set of sequences from each OTU was selected
for taxonomic identification of each OTU using the Ribosomal Database Project (RDP)
classifier.34 The Greengenes OTUs (4feb2011 build) reference sequences (97% sequence
similarity) were used as the training sequences for RDP. A 0.80 confidence threshold was
used for taxonomic assignment.
Arsenic speciation
Arsenic species were measured using an Agilent 7500 ICP-MS (Santa Clara, CA), as
described previously.35 The ICP-MS was interfaced with an Agilent 1260 HPLC, and a
Hamilton PRP-X100 column was used to separate arsenic species. The mobile phase A was
10 mM ammonium carbonate and 10 mM TRIS (pH=8.7), and the mobile phase B included
10 mM ammonium carbonate, 10 mM TRIS and 15 mM ammonium sulfate (pH 8.0). The
following gradient was run: 0 – 5 min 0% B to 100% B, 5–11 min 100% B, 11-16 min 100%
A. Sample preparation was conducted as follows: 10 μL of urine sample or arsenic reference
standards was diluted with 0.1 M ammonium acetate, pH=5, to make a total volume of 40
μL in a polypropylene microcentrifuge tube. Microcentrifuge tubes containing samples were
centrifuged for 5 min at 12,000 rpm at 4 °C in a refrigerated centrifuge. Following
centrifugation, 35 μL of supernatant was transferred to an HPLC autosampler vial, without
disturbing the solid pellet at the bottom of the tube, followed by injection of 5-10 μL into the
mass spectrometer.
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Statistical analysis
Data analysis was conducted with multivariate statistical methods to compare gut
microbiome communities between groups. Principal coordinate analysis (PCoA) was
performed to examine intrinsic clusters within the observations. In addition, Jackknifed beta
diversity and hierarchical clustering analysis via Unweighted Pair Group Method with
Arithmetic mean (UPGMAD) was used to differentiate the gut microbiome profiles of the
controls and infected samples. The difference in the individual gut microbiome composition
between control and treatment groups was assessed using a non-parametric test with
Metastats as described previously.36 The abundance of arsenic species in the control and
treatment groups were compared by Student's t test, and results were considered significant
when p < 0.05. The correlation between different arsenic metabolites was generated using
Pearson's correlation coefficient. One-way ANOVA with repeated measures was used to
assess the time effect of gut microbiome changes on arsenic metabolites. A linear mixed
statistical model was also applied to examine the impact of gut microbiome alterations on
the formation of arsenic species. All data handling and statistical analyses were performed
using the statistical R package or SAS.
3. Results
3.1 Experimental workflow
Figure 1 shows the experimental workflow for the 16S rRNA sequencing and arsenic
metabolite profiling. First, two groups of mice (B and D groups, 10/each group) were
infected with H. troguntum with three doses in a week, as described previously.37 Next,
arsenic was administrated to two groups of mice (one control, and another consisting of
mice with altered gut microbiome arising from bacterial infection, i.e. C and D groups in
Figure 1). For the gut microbiome profiling, DNA was isolated from fecal pellets, amplified
by PCR using 16S rRNA specific primers, and followed by 150 × 150 bp paired-end
sequencing using an Illumina Miseq platform. The resultant sequencing reads were
processed by the QIIME and Metastats software packages to reveal infection-induced gut
microbiome changes. For arsenic speciation analysis, urine was collected and analyzed by
HPLC-ICP-MS using a Hamilton PRP-X100 column. The resultant intensity counts (m/z =
75) of each arsenic metabolite were further normalized to reduce the impact of individual
variations of animals on uptaking arsenic during exposure, followed by statistical analysis to
reveal any altered metabolites between the control and treatment group. Urine samples were
collected at multiple time points including 1 day, 1, week, 2 and 4 weeks to examine
potential dynamic effects of gut microbiome changes on the metabolism of arsenic.
3.2 Arsenic speciation by ICP-MS
Figure 2A illustrates an arsenic metabolism pathway that involves reduction, methylation
and thiolation, with 8 major arsenic metabolites being measured. The formation of
DMTAsV is unique, as gut bacteria are important in the generation of this thiolated arsenic
metabolite. Figure 2B shows a HPLC-ICP-MS chromatogram from the urine sample of a
mouse exposed to iAsIII for 1 week. AsB and TMAsO eluted first but overlapped, followed
by iAsIII, MMAsIII, DMAsV, MMAsV, iAsV and DMTAsV. Among these arsenic species,
DMAsV is predominant (∼90% counts), followed by iAsV (∼5% counts), and the
remaining arsenic metabolites account for a total of ∼5% counts, as illustrated in Figure 2C.
DMAsIII could not be resolved on the column as it coeluted with the large peak of DMAsV.
3.3 Gut microbiome changes induced by bacteria
As described in the method section, H. trogontum was used to disturb the gut microbiome to
construct an animal model with bacterial-induced gut microbiome alterations and also to
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serve as a model to understand how infection influences individual's response to
environmental chemicals.
To probe gut microbiome changes arising from bacterial infection, 16S rRNA gene
sequencing was conducted. Figure 3A shows the identified gut bacteria assigned at family
level from 16S rRNA sequencing reads, with each color representing an individual bacterial
family. In terms of the assignment at phylum level, Fimicutes (53.7%) and Bacteroidetes
(41.1%) are predominant in the gut bacteria of mice, followed by Tenericutes (2.7%),
Actinobacteria (0.2%), Cyanobacteria (0.05%) and Proteobacteria (0.02%), with 2.2%
sequences unmatched with the database (Figure S1). The observations and assignments of
gut bacteria at phylum level are consistent with previous reports that the gut microbiome
consists of only several phyla.38 Figure 3B further illustrates all the gut bacteria families in
control and infection groups, as revealed by 16S sequencing at the family level. The forward
read and reverse read identify similar numbers and consistent types of gut bacteria at the
family level, with 42 and 46 for the forward and reverse read, respectively. Significantly
changed gut bacteria families (those above the dotted line, p<0.05) are illustrated in the
Figure 3B and their family level taxa assignments and fold changes are illustrated in Figure
3C. In addition to helicobacter detected in the infection group only, two Bacteroidetes
families increased ∼2000 and 15 fold compared to control
(p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Porphyromonadaceae and
p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;Other). Five bacterial families belonging to
Firmicutes were all down-regulated in infected animals, with fold changes from -2 to -11.
The difference in the gut microbiome patterns arising from H. trogontum infection could be
readily differentiated when comparing beta diversity UniFrac distances,39,40 as shown by the
PCoA plot in Figure 4A. The control (Red) and treated animals (Blue) are well separated,
with 22.8%, 12.1% and 8.6% variation explained by PC1, PC2 and PC3, respectively.
Consistent with the PCoA plot, the Jackknifed beta diversity and hierarchical clustering
analysis via UPGMAD demonstrate that infected animals and controls typically cluster in
their own groups, but with one treated mouse being grouped with the control group, as
shown in Figure 4B.
3.4 Histological analysis
Histology analysis was also conducted to examine whether H. trogontum infection caused
detectable tissue pathological changes. Histological scoring revealed no statistically
significant differences between the controls and infected animals in terms of inflammation,
edema, epithelial defects, crypt atrophy, hyperplasia and dysplasia in multiple regions of
liver and colon (Figure S2). These histological results are consistent with previous studies,
which reveal that C57BL/6 mice are not susceptible to lower bowel inflammation due to
Helicobacter spp. infection, despite persistent infection.37
3.5 Gut microbiome affects the metabolism of arsenic
As shown in Figure 3 and 4, the gut microbiome was significantly perturbed by H.
trogontum infection. We next compared the relative abundance of measured arsenic species
to examine whether the gut microbiome alterations impact the biotransformation of arsenic,
as shown in Figure 5 A to F. DMTAsV, a gut-flora-generated thiolated arsenic metabolite,
DMAsV and MMAsIII were significantly decreased after 1 day post arsenic exposure, while
iAsV was increased in the infection group, suggesting that gut microbiome changes resulting
from bacterial infection inhibit the detoxification of arsenic. Moreover, inorganic arsenic
(iAsV) in urine from 1 day-exposed mice is highly negatively correlated with methylated
and thiolated arsenic metabolites, including DMAsV and DMTAsV, as shown in Figure S3.
Similar to the case of 1 day exposure, iAsV was increased, while methylated arsenic
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metabolites, such as DMAsV, were significantly down-regulated at other time points,
including 1 week or 2 weeks post arsenic exposure. These findings clearly indicate that
bacterial infection-induced gut microbiome changes alter the reduction, methylation and
thiolation of arsenic, and consequently inhibit its detoxification.
It is well documented that the establishment or recovery of the gut microbiome is a temporal
process.41-43 Thus, the interaction between the gut microbiome and arsenic metabolism
could be dynamic. Figure S4 A and B illustrate the time effects of gut microbiome on the
formation of DMTAsV. Although there is no time dependence for DMTAsV in the control
groups, a statistically significant time-dependent effect was observed in infection groups
(p<0.005), highlighting a potential dynamic impact of gut microbiome changes on the
biotransformation of arsenic. Time-dependent effects were observed for the formation of
DMAsV in both controls and treated animals, as shown in Figure S4 C and D. However, a
linear mixed statistical model further identified the influence of gut microbiome
perturbations on the methylation of arsenic, with the intercepts of 0.0017 and 0.0032 being
determined for the control and treatment groups, respectively.
4. Discussion
In this study, we used a bacterial-infection animal model, high-throughput 16S rRNA gene
sequencing and ICP-MS based arsenic speciation to study the impact of bacterial-induced
gut microbiome perturbations on the biotransformation of arsenic. The data clearly
demonstrated that bacterial infection caused significant changes in the gut microbiome of
mice, which in turn affected the spectrum of metabolized arsenic species in mice. These
findings may provide novel mechanistic insights regarding the gut microbiome as a new risk
factor of individual responses when exposed to diverse environmental chemicals.
We used bacterium-infected mice as an animal model to probe the impact of gut microbiome
changes on arsenic metabolism. This selection was grounded in the understanding that
bacterial infections are naturally-occurring and universal. More importantly, infectious
diseases have been intertwined with environmental exposure in complex human exposure
scenarios, but the role of infection is not often well-considered in the common toxicological
paradigm.44 Our results are a beginning insight into the relationships between bacterial
infections and environmental exposures, and their consequent impacts on the toxicity of
toxicants. Specifically, we discovered that several gut bacteria families changed arising from
H. trogontum infection, as shown in Figure 3. In addition to the H. trogontum, another two
Bacteroidetes families were significantly up-regulated. They increased ∼2000 and 15 fold
compared to control, respectively
(p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Porphyromonadaceae and
p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;Other). Porphyromonadaceae is a family of
pathogenic bacteria generally composed of two genera of environmental bacteria,
g_Porphyromonas and g_Dysgonomonas.45 Thus, it appears that H. trogontum infection
increases the expansion of opportunistic pathogens. Five bacterial families belonging to
Firmicutes were all down-regulated in infected animals, with fold changes ranging from -2
to -11. These data clearly demonstrated that bacterial infection significantly altered the gut
microbiome. It should be noted that our analyses were conducted at the family level due to
higher confidence in the assignment of taxa based on the sequencing reads, therefore, a
significant change at the family level may reflect changes of multiple gut bacteria at genus
and species levels.
To examine whether infection and perturbed gut microbiome impact the biotransformation
of arsenic, we measured arsenic species in urine and found a significant change in the
spectrum of arsenic metabolites. Among of these disturbed arsenic metabolites, DMTAsV is
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of particular interest, since previous studies have documented that thiolation of arsenic could
be carried out by the gut microflora.13,14 For example, the capacity of the anaerobic
microflora from a mouse cecum to metabolize dimethylarsinic acid was examined, and
DMAsV was thiolated to DMTAsV and dimethyldithioarsinic acid (DMDTAs) after
incubated under anaerobic conditions at 37°C for up to 24 hours.13 Another study, taking
advantage of a dynamic model of the human gut, discovered that microbial thiolation led to
an additional thiolated arsenic metabolite, MMMTAsV, after incubating the colon
microbiata with iAs and As-contaminated urban soils.14 Moreover, urine analysis after iAs
exposure has already revealed the formation of both DMTAsV and MMMTAsV in animals
and humans.46,47 In this study, we measured the abundance of DMTAsV, which was
significantly different between the control and treatment group at 1 day and 2 week post-
exposure to arsenic. For example, DMTAsV was decreased in urine (fold change=∼-1.5,
p<0.05) after a 1-day exposure in mice with disturbed gut microbiome, highlighting the role
of the gut flora on generating thiolated arsenic species.
Methylation has long been considered a detoxification pathway, with As3mt being the
primary enzyme for the methylation of arsenic. As3mt is widely distributed in tissues, such
as liver, kidney, testis, and lung,25 and plays a key role in arsenic metabolism and toxicity,
as revealed by a few studies using As3mt knockout mice.48-51 In addition to the methylation
catalyzed by As3mt, a high degree of methylation of iAs (10 μg methylarsenical/g biomass/
hr) and As-contaminated soils (up to 28 μg/g biomass/hr) by the gut microbiota was also
reported.14 DMAsV is the primary metabolite during arsenic detoxification and is readily
excreted in urine. In this study, we discovered that DMAsV excretion in urine was lower in
the treatment group and typically accompanied by increased inorganic arsenic species,
indicating the detoxification was impaired by the gut microbiome perturbations. Since both
tissue enzymes and gut microflora are responsible for the methylation of arsenic, any
measurement on methylated arsenic species reflects the superimposed effects of both
factors. Significantly modulated DMAsV may therefore result from perturbed gut
microbiome communities or changes in As metabolic capacity of tissues during infection.
Previous studies, however, have revealed that gut microbiome changes can also induce
different expressions of liver metabolizing enzymes and functions of other organs distant
from the gut.22,43 For instance, colonization of gut bacteria was associated with
modifications of hepatic Cyp8b1 expression and the subsequent alteration of bile acid
metabolites, including taurocholate and tauromuricholate.22 Expression and activity of
major drug-metabolizing enzymes, such as Cyp3A11 and Cyp2C29, were also significantly
stimulated by gut microbiome changes.22 The systemic effects of the gut microbiome can
even reach the brain, and microbial colonization initiates signaling mechanisms that affect
neuronal circuits involved in motor control and anxiety behavior.43 It is therefore also likely
that enzyme systems that regulate the metabolism of arsenic could be modulated by gut
microbiome perturbations, which in turn contribute to reduced methylation capacity in the
treatment group. Answers to this intriguing question await future experiments.
There is considerable individual variation in arsenic metabolism and toxicity,52-55 and some
individuals methylate and excrete arsenic less efficiently than others, which could place
them at higher risks at developing arsenic-induced diseases. Different mechanisms for these
variations e.g., genetic variants, epigenetic regulation, and nutrition homeostasis, have been
proposed.56-58 Genetic susceptibility factors for arsenic-induced diseases have been
extensively studied.59-61 For example, single nucleotide polymorphisms of four genes,
including purine nucleoside phosphorylase (PNP), As3mt, glutathione S-transferase omega 1
and omega 2, which mediate multiple-step metabolism of arsenic through sequential
reduction and oxidative methylation, were examined and three exonic polymorphisms,
His20His, Gly51Ser, and Pro57Pro of PNP, were recently found to be associated with
arsenicism.60 The abundance and patterns of arsenic species have long been closely
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associated with toxicity in individuals exposed to arsenic, with the MMAsV/DMAsV ratio
showing a positive association with arsenic toxicity in several studies.61,62 In particular,
large individual variations in the gut microbiome and metagenomic genotypes have been
reported by others.63-65 In this complementary and specific study, we showed that infection-
induced gut microbiome perturbations affect the spectra of arsenic metabolites, thus
implicating the gut microbiome as a potential risk factor associated with individual
susceptibility to arsenic exposure.
We have also demonstrated that the infection and/or gut microbiome has a dynamic effect
on the spectra of arsenic metabolites (Figure S4), which may reflect the temporal
establishment of the gut microbiome communities following infection. It is well documented
that infants acquire their gut microbiome from the environment through the interaction with
their mothers,66 and that the establishment of the gut microflora is a temporal process, with
bacterial abundances increasing ∼ 6 orders of magnitude within weeks of life and becoming
more adult-like within the first year of life.41 Similarly, animal studies also show that
reconstruction of the gut microbiota ecosystem in germ-free mice through colonization of
gut bacteria is a dynamic event, and gut microbiome compositions in colonized mice are
highly time-dependent.22 In particular, we discovered that the formation of DMTAsV, a gut-
flora-generated arsenic metabolite, is time-dependent, highlighting the dynamic effects of
gut microbiome changes on the biotransformation of specific arsenic metabolites.
Measuring arsenic species in urine only represents a limitation of the study, since these data
do not reveal the retention/redistribution of As species in tissues. Future studies are needed
to pinpoint the effect of bacterial infection on the tissue arsenic burden. In addition, we took
advantage of an animal model with perturbed gut microbiome from bacterial infections to
emulate naturally-occurring and universal events in human exposure scenarios. Although it
has been demonstrated that C57BL/6 mice are not susceptible to Helicobacter spp. and
infection-induced immune response is limited, it would be challenging to completely rule
out the role of immune response in regulating arsenic biotransformation, since the immune
system is intrinsically intertwined with the gut microbiome. Animal models established via
other approaches, such as transplantation of the caecal microbiota, may serve as better tools
to further elucidate the role of the gut microbiome in mediating arsenic metabolism in future
studies.
In summary, we have combined an animal model with altered gut microbiome, 16S rRNA
gene sequencing and arsenic speciation to analyze the impact of gut microbiome changes on
the biotransformation of arsenic. Several arsenic species were significantly modulated by
gut microbiome perturbations resulting from bacterial infection, and a dynamic effect of gut
microbiome on the metabolism of arsenic was also revealed. Taken together, these data
show that gut microbiome compositions play a role in defining the abundance of specific
toxic species, supporting the hypothesis that gut microbiome phenotypes affect the spectra
of arsenic metabolites. The finding that bacterial infection impacts the biotransformation of
arsenic may improve our understanding how infectious diseases and environmental exposure
interact. Moreover, this study highlights the gut microbiome phenotype as a potential novel
risk factor associated with individual susceptibility to diverse environmental chemicals.
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ICP-MS Inductively coupled plasma mass spectrometry
H. Helicobacter
SAM S-adenosylmethionine
iAs Inorganic arsenic
MMAsV monomethylarsonic acid
MMAsIII monomethylarsonous acid
DMAsV dimethylarsinic acid
DMAsIII dimethylarsinous acid
MMAsV monomethylarsonic acid
DMTAsV dimethylmonothioarsinic acid
MMMTAsV monomethylmonothioarsonic acid
AsB arsenobetaine
TMAsO trimethyl arsine oxide
QIIME Quantitative Insights into Microbial Ecology
OTUs Operational Taxonomic Units
RDP Ribosomal Database Project
PCoA Principal coordinate analysis
UPGMAD Unweighted Pair Group Method with Arithmetic mean
DMDTAs dimethyldithioarsinic acid
As3mt arsenic (+3 oxidation state) methyltransferase
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Figure 1.
The integration approach combining a bacterial-infection animal model, 16S rRNA gene
sequencing and ICP-MS-based arsenic speciation to explore the impact of gut microbiome
changes on the biotransformation of arsenic. (Helicobacter troguntum: H.t.)
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Figure 2.
The metabolism pathway and major arsenic species (A), the ICP-MS chromatogram of urine
sample from a mouse exposed to 10 ppm arsenic (B), and the relative abundance of different
arsenic species after normalization using the total counts of arsenic at m/z = 75, with
DMAsV and iAsV being the top 2 arsenic metabolites (C).
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Figure 3.
Major gut bacteria at family level in individual animals, as revealed by 16S rRNA
sequencing, with each color being one bacterial family (A); Statistically significantly altered
gut bacterial families (those above the dotted line, p<0.05) by 16S rRNA gene sequencing
forward and reverse reads (B); The fold changes and taxa assignments of perturbed gut
bacteria at family level in infected mice compared to controls (C). (p: phylum; c: class; o:
order; f: family, ∞: helicobacter was detected only in the infection group).
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Figure 4.
The gut microbiome patterns of control samples (Red) and infected (Blue) mice are readily
differentiated by Principal Coordinate Analysis (PCoA), with 22.8%, 12.1% and 8.6%
variation explained by PC1, PC2 and PC3, respectively (A); Hierarchical Clustering analysis
by Unweighted Pair Group Method with Arithmetic mean indicates that controls and
infected mice cluster in their own groups (Red for control, Blue for treatment group) (B).
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Figure 5.
Arsenic metabolites were statistically significantly disturbed in infected animals compared
to the controls (p<0.05), with inorganic arsenic species, methylated and thiolated arsenic
metabolites being perturbed at multiple time points: DMTAsV (A), iAsV (B), DMAsV (C),
iAsIII (D), MMAsIII (E) and MMAsV (F). (Red: Controls; Blue: infection groups).
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